Loading
Life sciences · Journal article
Applied Sciences · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prototype development and feasibility study of a portable 13.56 MHz RF hyperthermia device tested in three human cell lines in vitro. The system achieved target temperatures (40–50 °C) and induced cell death in cancer cell lines in a temperature- and cell-type-dependent manner, but lacked selectivity for cancer over non-cancerous cells and did not include mechanistic characterization or statistical power analysis.
Single-arm in vitro device validation study. Three human cell lines: A549 (lung carcinoma), MDA-MB-231 (breast adenocarcinoma), and HUVEC (non-cancerous umbilical vein endothelial cells).. Intervention: RF hyperthermia exposure at 13.56 MHz, 40 W or 50 W for 10 minutes, generating temperatures of 40–50 °C.. Compared with: Untreated control cells..
System generated temperatures ranging from 40 to 50 °C depending on applied RF power and experimental conditions. MDA-MB-231 cells showed significantly increased apoptotic populations compared with untreated controls in response to RF exposure. A549 cells exhibited temperature-dependent shift toward increased necrosis at higher power levels (40 W and 50 W for 10 min).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work establishes technical feasibility of a portable RF hyperthermia platform for controlled laboratory use but does not yet support clinical translation. Further mechanistic studies and animal models are needed before evaluation in human subjects.
First-generation technical development with in vitro proof-of-concept in cancer cell lines; lacks clinical outcome, adequate power analysis, or comparative control to support stronger evidence classification.
As stated by the source record.
Quoted from the source exactly as published.
This work establishes technical feasibility of a portable RF hyperthermia platform for controlled laboratory use but does not yet support clinical translation. Further mechanistic studies and animal models are needed before evaluation in human subjects.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Hyperthermia is an adjunct therapeutic approach that induces stress responses in biological tissues via controlled heat and can enhance cancer therapy. However, many RF-based systems are fixed and limited in experimental flexibility. Therefore, the development of portable RF hyperthermia platforms is essential for in vitro optimization and preclinical investigations. This study developed a mobile 13.56 MHz RF hyperthermia system and evaluated its thermal performance and preliminary in vitro biological effects. A mobile prototype including an RF generator, matching unit, electrode chamber, sample holder, and touchscreen interface was built. Human cancer cell lines (A549 and MDA-MB-231) and non-cancerous HUVEC cells were exposed to RF power levels of 40 W and 50 W for 10 min to assess the biological effects of thermal exposure. Apoptotic responses were analyzed by Annexin V-FITC/PI flow cytometry. The system generated temperatures ranging from 40 to 50 °C depending on the applied RF power and experimental conditions. RF exposure increased apoptotic populations in a cell-dependent manner. MDA-MB-231 cells showed significantly increased apoptotic populations compared with their corresponding untreated controls, whereas A549 cells exhibited a temperature-dependent shift toward increased necrosis at higher power levels. HUVEC responses indicated limited selectivity under the tested conditions. Overall, the developed platform demonstrated both technical feasibility and biological activity, providing a practical tool for controlled in vitro RF hyperthermia studies. The findings support further mechanistic investigations and future preclinical studies aimed at optimizing RF-assisted therapeutic strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.